Buy Generic Uroxatral Online

Generic Uroxatral Information

Introduction

Uroxatral (alfuzosin) is an α‑adrenergic blocker indicated for the medical management of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult men. In Hong Kong, BPH is a common age‑related condition, affecting an estimated 15 % of men over 50 years and up to 30 % of those over 70 years. The medication belongs to the “Men’s Health” therapeutic group and is marketed by Mylan (a Viatris company). While its primary use is to relieve urinary obstruction caused by an enlarged prostate, alfuzosin’s pharmacologic profile also makes it useful for certain stress‑induced urinary issues.

What is Uroxatral?

Uroxatral is a prescription‑only oral tablet that contains the active pharmaceutical ingredient alfuzosin hydrochloride (5 mg per tablet). Alfuzosin is a selective α₁‑adrenergic receptor antagonist that was first synthesized in the early 199s and approved for BPH treatment in the United States in 2003. The product is manufactured under Good Manufacturing Practice (GMP) conditions and is distributed in Hong Kong by Mylan, which ensures batch‑to‑batch consistency and compliance with the Hong Kong Pharmacy and Poisons Ordinance.

How Uroxatral Works

Alfuzosin binds competitively to α₁‑adrenergic receptors located in the smooth muscle of the prostate, bladder neck, and urethra. By blocking these receptors, the drug prevents norepinephrine‑induced contraction of smooth muscle, resulting in reduced urethral resistance and improved urine flow. The onset of symptomatic relief typically occurs within 3 – 5 days of daily dosing, and steady‑state plasma concentrations are reached after about 5 days because the drug has a half‑life of roughly 10 hours. Alfuzosin is extensively metabolized by the liver (CYP3A4) and eliminated primarily in the feces, which minimizes accumulation in patients with mild‑to‑moderate renal impairment.

Conditions Treated with Uroxatral

• Benign Prostatic Hyperplasia (BPH) with LUTS – The FDA‑approved and Hong Kong‑recognized indication. Symptoms include nocturia, weak urinary stream, urgency, and incomplete bladder emptying.
• Secondary urinary obstruction related to prostatitis – While not a formal indication, clinicians may prescribe alfuzosin off‑label to alleviate dynamic obstruction when inflammation co‑exists with BPH.

Epidemiologically, BPH accounts for a substantial proportion of urology clinic visits in Hong Kong’s public hospitals. The drug’s ability to improve the International Prostate Symptom Score (IPSS) by an average of 5 – 7 points in randomized controlled trials supports its routine use in this population.

Who is Uroxatral For?

Uroxatral is appropriate for adult men who:

• Have been diagnosed with BPH and exhibit moderate to severe LUTS that interfere with daily activities.
• Prefer a once‑daily dosing regimen without the need for dose titration.
• Have stable cardiovascular status (e.g., no uncontrolled orthostatic hypotension).

Patients in whom Uroxatral may be unsuitable include:

• Men with a known hypersensitivity to alfuzosin or any excipients in the tablet formulation.
• Individuals taking strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that could raise plasma alfuzosin levels.
• Patients with severe hepatic impairment (Child‑Pugh C) because metabolism is compromised.

Risks, Side Effects, and Interactions

Common

• Dizziness or light‑headedness, especially after the first few doses.
• Headache.
• Nasal congestion or runny nose.
• Weakness or fatigue.

Rare

• Postural hypotension leading to fainting (syncope).
• Erectile dysfunction or decreased libido.
• Gastrointestinal upset (nausea, dyspepsia).

Serious

• Severe hypotension causing falls or traumatic injury.
• Prolonged QT interval (rare, observed in patients with pre‑existing cardiac conduction abnormalities).
• Anaphylactic reactions, including rash, swelling of the face or throat, and respiratory distress.

Clinically Relevant Drug–Drug Interactions

• CYP3A4 inhibitors (e.g., itraconazole, erythromycin) → increase alfuzosin plasma concentration; dose reduction or avoidance recommended.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine) → decrease efficacy; consider alternative therapy.
• Other α‑blockers (e.g., tamsulosin, prazosin) → additive hypotensive effect; monitor blood pressure closely.
• Nitrates (e.g., glyceryl trinitrate) → synergistic vasodilation, risk of marked hypotension.

Patients should disclose all prescription, over‑the‑counter, and herbal products to their healthcare provider before initiating Uroxatral.

Practical Use: Dosing, Missed Dose, Overdose

• Standard Dose: One 10 mg tablet taken once daily, preferably after the evening meal to reduce the likelihood of post‑ural hypotension. The 5 mg tablet is used only when dose reduction is clinically indicated (e.g., frail elderly).
• Missed Dose: If a dose is missed, take it as soon as remembered unless it is within 12 hours of the next scheduled dose; in that case, skip the missed tablet and resume the regular schedule. Do not double‑dose.
• Overdose: Symptoms may include profound dizziness, fainting, and severe hypotension. Seek immediate medical attention; supportive measures such as intravenous fluids and monitoring of blood pressure are standard.
• Food & Alcohol: High‑fat meals do not significantly affect absorption, but alcohol can exacerbate hypotensive effects; patients are advised to limit alcohol intake, especially when first starting therapy.
• Comorbidities: In patients with moderate hepatic impairment (Child‑Pugh B), the 5 mg dose is recommended. Renal function does not require routine dose adjustment unless severe (eGFR < 30 mL/min/1.73 m²).

Buying Uroxatral from Our Online Pharmacy

Uroxatral can be purchased safely from our online pharmacy in Hong Kong. Our service offers:

• Competitive pricing – We source the medication directly from licensed overseas manufacturers, providing a cost close to the international reference price.
• Verified quality – Every batch is verified by third‑party laboratories for potency, purity, and compliance with pharmacopeial standards.
• Discrete, reliable delivery – Orders are packed in unmarked packaging and dispatched via express courier (usually within 7 days) or regular airmail (approximately 3 weeks).
• Pharmacy‑broker model – We act as a broker between Hong Kong patients and accredited overseas pharmacies, ensuring that the medication complies with local regulatory requirements while maintaining patient privacy.

For patients who encounter limited insurance coverage, long waiting periods at public hospitals, or difficulty locating the medication in local retail pharmacies, our platform provides a convenient, cost‑effective alternative.

FAQ

• Is Uroxatral available in both brand‑name and generic forms in Hong Kong?
  Yes. The brand‑name product is marketed as Uroxatral, while generic versions containing the same active ingredient, alfuzosin, are also approved by the Hong Kong Department of Health. Generic options are typically less expensive and are widely prescribed.

• How should Uroxatral be stored in Hong Kong’s humid climate?
  Store the tablets at a controlled room temperature of 15 °C – 30 °C, away from excess humidity, direct sunlight, and heat sources. A kitchen cabinet or a sealed plastic container can protect the medication from moisture.

• What does the tablet look like, and how can I identify it?
  roxatral tablets are oval, film‑coated, and usually white to off‑white. Imprints vary by manufacturer; the generic version often bears the letters “ALF” followed by the strength (e.g., “5 mg”). Always verify the imprint against the packaging insert.

• Can I travel internationally with Uroxatral in my carry‑on luggage?
  Yes, provided the medication is in its original packaging with a copy of the prescription or a doctor’s note. Some countries require declaration of prescription drugs; check the destination’s customs regulations before travel.

• Does alfuzosin interact with herbal supplements such as St. John’s wort?
  St. John’s wort is a known CYP3A4 inducer, which may lower alfuzosin plasma levels and reduce its effectiveness. Patients using this supplement should discuss potential dose adjustments with their healthcare provider.

• Are there any differences in formulation between Uroxatral sold in the United States and Asia?
  The active ingredient, alfuzosin hydrochloride, is identical worldwide. Excipients such as lactose, magnesium stearate, and film‑coating polymers may vary slightly to meet regional manufacturing standards, but these differences do not alter clinical efficacy.

• What special warnings exist for Asian populations taking alfuzosin?
  Clinical data have not identified ethnicity‑specific safety concerns. However, Asians may have a higher prevalence of certain CYP3A4 polymorphisms that could affect drug metabolism; clinicians may monitor blood pressure more closely during initial therapy.

• Can Uroxatral be used in patients with diabetes who experience frequent urination?
  Alfuzosin treats the obstructive component of urinary symptoms but does not address polyuria caused by uncontrolled diabetes. It may be prescribed if BPH contributes to the urgency, but optimal glycemic control remains essential.

• What is the shelf‑life of Uroxatral tablets?
  The product generally retains full potency for 24 months when stored under recommended conditions. The expiration date is printed on the outer blister pack; do not use tablets beyond this date.

• Is a urine test affected by taking alfuzosin?
  Alfuzosin is not a prohibited substance in standard workplace or sports drug testing panels. It does not produce false‑positive results for common screens such as amphetamines or opioids.

Glossary

α₁‑Adrenergic Receptor

A protein on smooth‑muscle cells that, when activated by norepinephrine, causes contraction. Blocking this receptor relaxes the muscle.

Benign Prostatic Hyperplasia (BPH)

A non‑cancerous enlargement of the prostate gland that can compress the urethra, leading to lower urinary tract symptoms.

CYP3A4

An enzyme in the liver that metabolizes many medications, including alfuzosin. Inhibitors or inducers of this enzyme can alter drug concentrations.

Orthostatic Hypotension

A sudden drop in blood pressure upon standing, which can cause dizziness or fainting. Alfuzosin may precipitate this effect, especially after the first dose.

⚠️ Disclaimer

The information provided about Uroxatral is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Uroxatral for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.